{"a":[{"_":"Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push","$":{"href":"/biotech/electra-sets-plans-light-nasdaq-ipo-fuel-phase-23-trial-ii-asset","hreflang":"en"}}]}

IPO/OfferingPositive

AI Analysis

Electra Therapeutics has filed to go public via IPO to fund its immunology and cancer pipeline programs currently in Phase 2/3 development.

Phase

2/3

Importance:6/10

Sentiment:

0.40

IPOimmunologyoncologyPhase 2/3

Read the original article

Published by FierceBiotech on August 31, 2026 11:28 AM